NICE clears Mounjaro for NHS weight-management use

Britain's National Institute for Health and Care Excellence, known as NICE, gave final approval on December 23 for Eli Lilly's tirzepatide, sold as Mounjaro, to be used for weight management through the National Health Service ^[1]. The decision means the NHS becomes one of the first public health systems anywhere to fund the drug for obesity, not just diabetes ^[1].

Under the guidance, Mounjaro is recommended alongside diet and exercise changes for people with at least one weight-related condition, such as heart disease or type-2 diabetes, and a body mass index above 35 ^[1][2]. Those eligibility rules mirror the criteria NICE set in March 2023 for semaglutide's obesity brand, Wegovy ^[1][2]. NICE says about 3.4 million people in England could technically qualify under those criteria ^[1][2].

Because the NHS cannot treat everyone who qualifies at once, the rollout will be phased. NICE said about 220,000 people are expected to receive the drug over the first three years, with those judged to have the highest clinical need prioritized first ^[2]. NICE will review the program again within that three-year window ^[2]. Patients already being treated at a specialist NHS weight-management service could start receiving Mounjaro 90 days after the guidance was published, while others would have to wait 180 days ^[2].

The NHS will pay 122 pounds, or about $153, per patient per month for the highest dose, a price NICE judged to be cost-effective given what obesity and related conditions already cost the health system ^[1]. In clinical trials, Mounjaro produced weight loss of nearly 23% on average ^[1][2]. Nearly one in three adults in Britain are obese, the highest rate in Europe and above the European Union average of 16.5%, according to a 2019 OECD report cited by Reuters ^[2]. Before this decision, Mounjaro had only been available in Britain to people paying out of pocket, largely through online pharmacies, since it launched there in February 2024 ^[1][2].

Why it matters for patients

This is a British decision and does not change insurance coverage or pricing for tirzepatide, sold in the US as Mounjaro for diabetes and Zepbound for weight loss. But it is a signal US patients may find useful. It shows a major national health system concluding that tirzepatide is cost-effective for obesity treatment when paired with lifestyle changes, using eligibility rules almost identical to those already applied to semaglutide-based Wegovy ^[1][2].

The UK case also illustrates a problem that shows up in different forms in US insurance too: even when a drug is approved and judged cost-effective, health systems often cannot pay for every eligible patient immediately. NICE explicitly built in a phased approach, prioritizing higher-need patients first because the rollout has to be "carefully managed" so the system can still meet other health needs ^[2]. US patients navigating insurance prior authorization or step-therapy requirements may recognize this same tension between broad clinical eligibility and limited near-term capacity to serve everyone who qualifies.

What happens next

NICE published its final guidance on December 23, after no appeals were lodged ^[1]. NHS patients already being seen at specialist weight-management services could begin receiving Mounjaro starting around March 2025, roughly 90 days after publication, while other eligible patients would wait about 180 days, or into mid-2025 ^[1][2]. NICE said it will reassess the program's scope within the initial three-year rollout period ^[2]. Sources do not address whether this UK approach will influence US insurer or Medicare coverage policy for tirzepatide.